An interventional study of Adelmidrol 2% / Hyaluronic Acid 1% and micronized Palmitoylethanolamide (mPEA) 300mg + ultramicronized Palmitoylethanolamide (umPEA) 600mg in Degenerative Joint Disease of Knee and Rheumatoid Arthritis, sponsored by Universita di Verona. Not yet recruiting at 1 site in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Universita di Verona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Osteoarthritis, Knee with a site in Italy — 29 open to participants now, 33 under way, 3 of them phase 3. Osteoarthritis, Knee · Italy.
Among the 106 studies in Osteoarthritis, Knee with a site in Italy, this one is the 36th largest by planned enrollment of the 84 interventional ones that give a count, is one of 4 that started in 2026, is one of 59 with no phase, reaches primary completion later than 23 of the 32 other live ones, and was the 106th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →29 of the 106 studies in Osteoarthritis, Knee with a site in Italy are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Italy, United States, Australia and 7 more countries
Ages 18+
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–60
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40–65
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 65–80
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 10
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 65 across the 84 interventional studies, 103 across the 22 observational. Of the 62 that completed or were terminated, 11 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 106 have an industry lead sponsor. The 10 most frequent:
Universita di Verona is the lead sponsor of 125 studies on the registry; 27 are open to participants now.
Universita di Verona has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
7 of the studies in Osteoarthritis, Knee with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06726629Istituto Ortopedico RizzoliCrosscultural Adaptation And Validation Of The Italian Version Of The New Knee Society Knee Scoring System | 2026-11 |
| NCT06251752Istituto Ortopedico RizzoliLong Term Evaluation of Clinical and Radiologic Results on Femoro-patellar Joint After High Tibial Osteotomy | 2026-12 |
| NCT06040957Istituto Ortopedico RizzoliBone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis | 2027-01 |
| NCT07495618ASL LecceSurgeon Physiologic Stress During Unicompartmental Knee Arthroplasty: Manual vs Computer-Assisted Technique | 2027-03 |
| NCT06490770Istituto Ortopedico RizzoliAnalysis of the Pathophysiological and Functional State of the Knee Joint | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies in Osteoarthritis, Knee with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Degenerative knee joint diseases are characterized by chronic pain, inflammation, and functional impairment. In these conditions, mast cell density in the synovial membrane is increased, resulting in an excessive release of biological mediators involved in key mechanisms of neuroinflammation and in hyaluronic acid depolymerisation. Adelmidrol acts as a preventive antioxidant due to its radical scavenging activity, thus protecting hyaluronic acid from oxidative degradation and reducing mast cell degranulation. Furthermore, a reduction in endogenous Palmitoylethanolamide (PEA) levels also contributes to joint neuroinflammation and disease progression; therefore, its exogenous supplementation may represent a valuable supportive strategy.
The objective of this clinical investigation is to compare the efficacy of intra-articular adelmidrol/hyaluronic acid treatment alone versus the same intra-articular treatment combined with oral micronized /ultramicronized PEA in patients with knee joint degeneration due to osteoarthritis or rheumatoid arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive intra-articular injections of adelmidrol 2% / hyaluronic acid 1% (Hyadrol®) administered once weekly for three consecutive weeks.
Device: Adelmidrol 2% / Hyaluronic Acid 1%
Participants receive intra-articular injections of adelmidrol 2% / hyaluronic acid 1% (Hyadrol®) administered once weekly for three consecutive weeks, combined with oral micronized/ultramicronized palmitoylethanolamide (m-/um-PEA) (Normast® MPS), one sachet twice daily for 6 weeks, followed by 1 sachet daily for 8 weeks.
Device: Adelmidrol 2% / Hyaluronic Acid 1% · Dietary Supplement: micronized Palmitoylethanolamide (mPEA) 300mg + ultramicronized Palmitoylethanolamide (umPEA) 600mg
Ultrasound-guided intra-articular knee injection, 2 mL per injection, administered once weekly for three weeks.
Also known as: Hyadrol®
Drug page: PalmidrolStudies of PalmidrolPalmidrol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Oral administration of m-/um-PEA, one sachet twice daily for 6 weeks, followed by 1 sachet daily for 8 weeks.
Also known as: Normast® MPS
Change in joint symptoms and function
Evaluation of degenerative joint disease symptoms and function assessed by Western Ontario and McMaster Universities (WOMAC) scale, a self-report questionnaire consisting of 24 questions divided in pain (5 items), joint stiffness (2 items) and functional limitations (17 items). Each question has 5 possible answers, evaluated on a Likert scale, from 0 (none) to 4 (extreme): * pain: score from 0 to 20; * joint stiffness: score from 0 to 8; * functional limitations: score from 0 to 68. The sum of the individual scores results in an overall score from 0 to 96 (96 indicates severe disability).
Time frame: Baseline (T0) and 1 month after treatment (T3)
Change in WOMAC score
Evaluation of degenerative joint disease symptoms and function assessed by Western Ontario and McMaster Universities (WOMAC) scale, a self-report questionnaire consisting of 24 questions divided in pain (5 items), joint stiffness (2 items) and functional limitations (17 items).
Time frame: Baseline (T0), 1 week (T1), 2 weeks (T2), 3 months after treatment (T4) and 6 months after treatment (T5)
Change in pain intensity
Evaluation of pain intensity assessed by the Visual Analogue Scale (VAS) scored from 0 mm to 100 mm, where 0 indicates 'no pain' and 100 corresponds to 'the worst pain ever possible'. The higher the score, the more severe the pain.
Time frame: Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month after treatment (T3), 3 months after treatment (T4) and 6 months after treatment (T5)
Change in patients' quality of life
Quality of Life evaluated by the 12-Item Short Form Health Survey (SF-12). The SF-12 is a self-reported health questionnaire. The score produces two summary measures: a mental (MCS-12) and a physical component score (PCS-12). The PCS-12 score is derived from the subdimensions of general health, physical functioning, role physical, and bodily pain, while the MCS-12 score is derived from the subdimensions of social functioning, role emotional, mental health, and energy. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time frame: Baseline (T0), 1 month after treatment (T3), 3 months after treatment (T4) and 6 months after treatment (T5)
Incidence of Treatment-Related Adverse Events (Safety and Tolerability)
Treatment safety is assessed by monitoring the incidence and severity of adverse events immediately after injections and throughout the study.
Time frame: From first treatment administration up to 6 months after treatment
Change in analgesic consumption
Analgesic consumption is evaluated by the Cumulative Analgesic Consumption Score (CACS), an index that quantifies the overall use of analgesic medications, taking into account the type, dosage, and frequency of the different analgesics administered.
Time frame: Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month after treatment (T3), 3 months after treatment (T4) and 6 months after treatment (T5)
Change of patients' self-assessed health status
The patient's global health status is evaluated through the Likert Patient Global Impression of Change (PGIC) scored in 7 points (from 1, very much improved to 7, very much worse).
Time frame: 1 month after treatment (T3), 3 months after treatment (T4) and 6 months after treatment (T5)
Plan to share: No
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 12 months is below that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palmidrol